New insights into the molecular actions of nitrogen-containing bisphosphonates

Haematologica Reports

Volumn 2, Issue 3, 2006, Pages 24-25

  Rogers, M J ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; GERANYLTRANSFERASE; MINODRONIC ACID; NITROGEN; RISEDRONIC ACID; ZOLEDRONIC ACID;

CONFERENCE PAPER; DRUG BINDING; DRUG MECHANISM; DRUG METABOLISM; ENZYME INHIBITION; ENZYME KINETICS; HUMAN; OSTEOLYSIS; T LYMPHOCYTE ACTIVATION;

EID: 46749144589     PISSN: 18249337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)

1. Frith JC, MonkkonenJ, Blackburn GM, Russell RG, Rogers MJ. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma- dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 1997;12:1358-67.
2. Benford HL, Frith JC, Auriola S, Monkkonen J, Rogers MJ. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate Drugs Mol Pharmacol 1999;56:131-40.
3. Rogers MJ. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. Calcif Tissue Int 2004;75:451-1.
4. Frith JC, Monkkonen J, Auriola S, Monkkonen H, Rogers MJ. The molecular mechanism of action of the anti-resorptive and anti-inflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arth Rheum 2001;44:2201-10.
5. Lehenkari PP, Kellinsalmi M, Napankangas JP, Ylitalo KV, Monkkonen J, Rogers MJ. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol 2002;61:1255-62.
6. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003;9:2643-58.
7. Green JR, Rogers MJ. Pharmacologic profile of zoledronic acid: a highly potent inhibitor of bone resorption. Drug Dev Res 2002;55;210-24.
8. van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 1999;264:108-11.
9. Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000;373:231-41.
10. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino F H, Rogers MJ. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001;296:235-42.
11. Thompson K, Rogers MJ. Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro. J Bone Miner Res 2004;19:278-88.
12. Rondeau JM, Bitsch F, Geiser M, Hemmig R, Kroemer, Lehmann S. Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. J Med Chem in press.
13. Kavanagh K, Guo K, Wu X, Knapp S, EbetinoFH, Dunford JE. Human farnesyl diphosphate synthase (FDPS): crystal structure and molecular interactions with nitrogen-containing bisphosphonates. J Bone Miner Res 2005;20:95-6.
14. Martin MB, Arnold W, Heath HT, Urbina JA, Oldfield E. Nitrogen-Containing Bisphosphonates as Carbocation Transition State Analogs for Isoprenoid Biosynthesis. Biochem Biophys Res Commun 1999;263:754-8.
15. Hosfield DJ, Zhang Y, Dougan DR, Brooun A, Tari LW, Swanson RV. Structural basis for bisphosphonate-mediated inhibition of isoprenoid biosynthesis. J Biol Chem 2003;279:8526-9.
16. Ebetino FH, Roze CN, McKenna CE, Barnett BL, Dunford JE, Russell RGG, et al. Molecular interactions of nitrogen-containing bisphosphonates within farnesyl diphosphate synthase. J Organomet Chem 2005;690:2679-87.
17. Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003;197:163-8.